NASDAQ:IMRN - IMMURON Ltd/S Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $11.0775 +0.08 (+0.73 %) (As of 07/19/2018 03:33 PM ET)Previous Close$11.00Today's Range$10.31 - $11.2052-Week Range$4.47 - $16.70Volume2,848 shsAverage Volume8,083 shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia. Receive IMRN News and Ratings via Email Sign-up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:IMRN CUSIPN/A Webwww.immuron.com Phone61-3-9824-5254 Debt Debt-to-Equity RatioN/A Current Ratio5.24 Quick Ratio3.32 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.05 million Price / Sales1,506.33 Cash FlowN/A Price / CashN/A Book Value$0.04 per share Price / Book276.94 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees7 Outstanding Shares142,780,000Market Cap$1,580.56 IMMURON Ltd/S (NASDAQ:IMRN) Frequently Asked Questions What is IMMURON Ltd/S's stock symbol? IMMURON Ltd/S trades on the NASDAQ under the ticker symbol "IMRN." What price target have analysts set for IMRN? 1 analysts have issued twelve-month price objectives for IMMURON Ltd/S's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate IMMURON Ltd/S's share price to reach $20.00 in the next year. This suggests a possible upside of 80.5% from the stock's current price. View Analyst Ratings for IMMURON Ltd/S. What is the consensus analysts' recommendation for IMMURON Ltd/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMURON Ltd/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of IMMURON Ltd/S's key competitors? Some companies that are related to IMMURON Ltd/S include Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), United Therapeutics (UTHR), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH) and Array Biopharma (ARRY). Who are IMMURON Ltd/S's key executives? IMMURON Ltd/S's management team includes the folowing people: Dr. Jerry Kanellos Ph.D., Interim Chief Exec. Officer (Age 57)Mr. Peter Anastasiou, Exec. Vice Chairman (Age 58)Mr. Phillip Allen Hains, Joint CFO & Company Sec. (Age 59)Mr. Peter Vaughan, Joint CFO & Company Sec. (Age 35)Mr. David Lyon, Head of Marketing When did IMMURON Ltd/S IPO? (IMRN) raised $6 million in an initial public offering on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager. Has IMMURON Ltd/S been receiving favorable news coverage? Media coverage about IMRN stock has trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IMMURON Ltd/S earned a media sentiment score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 46.67 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of IMMURON Ltd/S? Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is IMMURON Ltd/S's stock price today? One share of IMRN stock can currently be purchased for approximately $11.0775. How big of a company is IMMURON Ltd/S? IMMURON Ltd/S has a market capitalization of $1.58 billion and generates $1.05 million in revenue each year. IMMURON Ltd/S employs 7 workers across the globe. How can I contact IMMURON Ltd/S? IMMURON Ltd/S's mailing address is 25 37 CHAPMAN STREET, VICTORIA C3, 3130. The company can be reached via phone at 61-3-9824-5254 or via email at [email protected] MarketBeat Community Rating for IMMURON Ltd/S (NASDAQ IMRN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 105 (Vote Outperform)Underperform Votes: 80 (Vote Underperform)Total Votes: 185MarketBeat's community ratings are surveys of what our community members think about IMMURON Ltd/S and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?